Cargando…

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

OBJECTIVES: To review published cost-effectiveness analyses (CEA) assessing bortezomib (BTZ) for multiple myeloma (MM) and explore possible bias affecting the cost-effectiveness of BTZ. METHODS: Literature was searched for published CEAs assessing BTZ or BTZ-containing regimens for MM from 2003 to 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wendong, Yang, Yicheng, Chen, Yi, Du, Fen, Zhan, Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861606/ https://www.ncbi.nlm.nih.gov/pubmed/27217786 http://dx.doi.org/10.2147/CEOR.S104195

Ejemplares similares

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
por: Cantadori, Lucas Oliveira, et al.
Publicado: (2022)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
por: Kozalak, Gül, et al.
Publicado: (2023)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
por: Sanz-Solas, Antonio, et al.
Publicado: (2023)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2019)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
por: Ye, Ziqi, et al.
Publicado: (2019)

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline
por: Reece, D., et al.
Publicado: (2006)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
por: Pancheri, Elia, et al.
Publicado: (2020)

Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
por: Ding, Kaixi, et al.
Publicado: (2022)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma
por: Chen, Runzhe, et al.
Publicado: (2017)

Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma
por: Fall, Deanna J., et al.
Publicado: (2014)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies
por: Zhu, Wanqiu, et al.
Publicado: (2016)

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
por: McCaughan, Georgia J., et al.
Publicado: (2022)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
por: Hu, Xiaotong, et al.
Publicado: (2014)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
por: Mateos, Maria V., et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_94rlil48m717j2phtn1v4t1g9i